Zacks Research Has Positive Outlook for IRWD Q4 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research raised their Q4 2026 earnings estimates for shares of Ironwood Pharmaceuticals in a research note issued on Tuesday, January 20th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of $0.23 per share for the quarter, up from their previous forecast of $0.16. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q3 2027 earnings at ($0.01) EPS.

Other analysts have also issued reports about the company. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Craig Hallum raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 29th. Citizens Jmp upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 target price on the stock in a research report on Monday, January 5th. Finally, Wells Fargo & Company boosted their target price on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $6.12.

Ironwood Pharmaceuticals Stock Up 1.8%

Shares of Ironwood Pharmaceuticals stock opened at $4.58 on Wednesday. The firm has a market cap of $745.07 million, a PE ratio of 28.63 and a beta of 0.18. Ironwood Pharmaceuticals has a twelve month low of $0.53 and a twelve month high of $5.78. The business has a 50-day moving average price of $3.65 and a 200 day moving average price of $2.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. The company had revenue of $122.06 million during the quarter, compared to analysts’ expectations of $74.22 million. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. Range Financial Group LLC purchased a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at about $1,436,000. Hennion & Walsh Asset Management Inc. grew its position in shares of Ironwood Pharmaceuticals by 15.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 196,032 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 26,539 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Ironwood Pharmaceuticals by 56.3% in the fourth quarter. SG Americas Securities LLC now owns 57,747 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 20,795 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 30.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,920,530 shares of the biotechnology company’s stock valued at $2,516,000 after purchasing an additional 445,484 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its position in Ironwood Pharmaceuticals by 351.2% during the third quarter. Public Employees Retirement System of Ohio now owns 60,768 shares of the biotechnology company’s stock worth $80,000 after buying an additional 47,299 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.